Stay updated on Pembrolizumab Combo in ES-SCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in ES-SCLC Clinical Trial page.

Latest updates to the Pembrolizumab Combo in ES-SCLC Clinical Trial page
- Check7 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.0%
- Check14 days agoNo Change Detected
- Check22 days agoChange DetectedThe page has been updated to reflect a new version of the study, with significant changes in the investigational agents being evaluated for the treatment of extensive-stage small cell lung cancer. Notably, the previous investigational agents have been removed, and new drugs such as Lenvatinib, Etoposide, Cisplatin, and Carboplatin have been added.SummaryDifference30%
- Check29 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
- Check36 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.0%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.7%
- Check87 days agoChange DetectedThe page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference0.7%
Stay in the know with updates to Pembrolizumab Combo in ES-SCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in ES-SCLC Clinical Trial page.